H. Lundbeck company profile
Company profile
H. Lundbeck has 5,000 employees and is headquartered in Valby, Denmark.
Patients with psychiatric and neurological disorders in Europe, the United States and other international markets are served by H. Lundbeck A/S, which researches, develops, manufactures and commercializes pharmaceuticals for these conditions, including schizophrenia, bipolar I disorder, depression, migraine, epilepsy, dementia and Parkinson's disease. Its products include Abilify Maintena, Brintellix, Rexulti, Vyepti and Azilect. Its pipeline includes Eptinezumab in phase 3 testing for cluster headache and bexicaserin in phase 3 for developmental and epileptic encephalopathies. A strategic research collaboration with Contera Pharma targets oligonucleotide-based medicines for serious neurological conditions. The company was founded in 1915.
In the fiscal year ended December 2025, revenue reached DKK 24.6 billion, up 11.9% from the previous year, and net profit came to DKK 3.2 billion. The company employs 5,000 people and is headquartered in Valby, Denmark.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Denmark
- Headquarters
- Ottiliavej 9, 2500, Valby
- Employees
- 5,000
- Listing
- HLUN.A · Nasdaq Copenhagen
- Currency
- DKK
- ISIN
- DK0061804697
- Website
- lundbeck.com
H. Lundbeck and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| H. LundbeckHLUN.A | Denmark | $8.49B | 5,000 | 24.4% | 14.2 |
| IpsenIPN | France | $14.2B | 5,535 | 27.4% | 25.5 |
| Swedish Orphan BiovitrumSOBI | Sweden | $16.27B | 2,207 | 30.9% | 25.0 |
| Laboratorios Farmaceuticos RoviROVI | Spain | $3.93B | 1,950 | 20.2% | 17.4 |
| Siegfried HoldingSFZN | Switzerland | $3.53B | 4,454 | 16.7% | 17.3 |
| AlmirallALM | Spain | $2.53B | 2,108 | 9.6% | 32.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
